A Canadian startup is out to rewrite one of the drug industry’s most painful cautionary tales, betting that an all-but-abandoned heart drug may actually work. But it’ll have to overcome significant evidence to the contrary and win over a deeply skeptical scientific establishment.

The company, DalCor Pharmaceuticals, is carrying the torch for the idea that improving good cholesterol, known as HDL, can prevent heart attacks and strokes for at-risk patients. It hopes its drug — part of a class of medicines called CETP inhibitors — can do just that by blocking what’s known as cholesterylester transfer protein.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy